# Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

> **NCT00427583** · PHASE2,PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 11 (actual)

## Conditions studied

- Malignant Peripheral Nerve Sheath Tumors

## Interventions

- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00427583
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2009-04
- **Final completion:** —
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** stopped due to slow recruitment and no effect
- **Last updated:** 2012-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427583, "Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00427583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*